These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1129 related articles for article (PubMed ID: 34887858)

  • 41. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
    Zou X; Hu Z; Huang C; Chang J
    Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
    Li X; Zhang D; Guo P; Ma S; Gao S; Li S; Yuan Y
    Aging (Albany NY); 2024 Apr; 16(7):6290-6313. PubMed ID: 38575204
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypoxia-related gene signature for predicting LUAD patients' prognosis and immune microenvironment.
    Chen J; Fu Y; Hu J; He J
    Cytokine; 2022 Apr; 152():155820. PubMed ID: 35176657
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
    Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
    Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Novel Gene Signature based on Immune Cell Infiltration Landscape Predicts Prognosis in Lung Adenocarcinoma Patients.
    Ma C
    Curr Med Chem; 2024; 31(38):6319-6335. PubMed ID: 38529604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Construction and validation of a cuproptosis-related lncRNA signature for the prediction of the prognosis of LUAD and LUSC.
    Wang Y; Xiao X; Li Y
    Sci Rep; 2023 Feb; 13(1):2477. PubMed ID: 36774418
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 50. Whole Exome and Transcriptome Analyses Integrated with Microenvironmental Immune Signatures of Lung Squamous Cell Carcinoma.
    Seo JS; Lee JW; Kim A; Shin JY; Jung YJ; Lee SB; Kim YH; Park S; Lee HJ; Park IK; Kang CH; Yun JY; Kim J; Kim YT
    Cancer Immunol Res; 2018 Jul; 6(7):848-859. PubMed ID: 29720381
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic model of lung adenocarcinoma constructed by the CENPA complex genes is closely related to immune infiltration.
    Zhou H; Bian T; Qian L; Zhao C; Zhang W; Zheng M; Zhou H; Liu L; Sun H; Li X; Zhang J; Liu Y
    Pathol Res Pract; 2021 Dec; 228():153680. PubMed ID: 34798483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers.
    Chen M; Liu X; Du J; Wang XJ; Xia L
    Oncotarget; 2017 Jan; 8(1):133-144. PubMed ID: 27863400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes.
    Isaeva OI; Sharonov GV; Serebrovskaya EO; Turchaninova MA; Zaretsky AR; Shugay M; Chudakov DM
    J Immunother Cancer; 2019 Oct; 7(1):279. PubMed ID: 31665076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
    Shu J; Jiang J; Zhao G
    Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased interleukin-17A-producing γδT cells predict favorable survival in elderly patients with LUAD and LUSC.
    Cui K; Mei X; Cheng M
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3289-3298. PubMed ID: 34327570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.
    Li L; Liu YD; Zhan YT; Zhu YH; Li Y; Xie D; Guan XY
    Thorac Cancer; 2018 Jul; 9(7):775-784. PubMed ID: 29722145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of prognostic signature related with twelve types of programmed cell death in lung squamous cell carcinoma.
    Li S; Ding B; Weng D
    J Cardiothorac Surg; 2024 Oct; 19(1):569. PubMed ID: 39354528
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
    Liang H; Li Y; Qu Y; Zhang L
    Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
    Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.